Page 1

August 3 , 2021 For Release : Final Refer to : ● Eli Lilly and Company Lilly Lilly Corporate Center Indianapolis , Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com Molly McCully ; mccully_molly@lilly.com ; ( 317 ) 478-5423 ( Media ) Kevin Hern ; hern_kevin_r@lilly.com ; ( 317 ) 277-1838 ( Investors ) Lilly Delivers Strong Second - Quarter 2021 Financial Results , Updates 2021 Financial Guidance Revenue in the second quarter of 2021 increased 23 percent , driven by volume growth of 22 percent . Revenue growth was 12 percent when excluding effects of 2020 COVID - related stocking patterns , revenue from COVID - 19 antibodies and recent business development . Year - to - date revenue grew 11 percent - excluding revenue from COVID - 19 antibodies - with strong sequential growth from first quarter to second quarter 2021 , suggesting continued recovery from the COVID - 19 pandemic in line with company expectations . Revenue from all key products grew in the quarter and 2021 year - to - date . These key growth products , consisting of Trulicity , Taltz , Verzenio , Jardiance , Emgality , Olumiant , Tyvyt , Retevmo , and Cyramza , contributed 17 percentage points of revenue growth and represented approximately 54 percent of total revenue in the second quarter of 2021 , excluding revenue from COVID - 19 antibodies . Notable pipeline events included positive data readouts for tirzepatide for type 2 diabetes and Jardiance for adults , with or without diabetes , who live with heart failure with preserved ejection fraction ( HFpEF ) . The company announced plans to submit donanemab for Alzheimer's disease and tirzepatide for type 2 diabetes to regulatory authorities by the end of 2021 . Second - quarter 2021 operating expenses increased 18 percent , driven primarily by higher research and development investments for late - stage assets , as well as higher relative marketing and selling expenses due to pandemic - related spending reductions in 2020 . Second - quarter 2021 earnings per share ( EPS ) decreased to $ 1.53 on a reported basis and increased to $ 1.87 on a non - GAAP basis . 2021 EPS guidance updated to be in the range of $ 6.73 to $ 6.93 on a reported basis and remains in the range of $ 7.80 to $ 8.00 on a non - GAAP basis . Eli Lilly and Company ( NYSE : LLY ) today announced financial results for the second quarter of 2021 .